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Abstract 
South Africa has more people infected with HIV but, by providing access to anti-retroviral therapy (ART), has kept more 
people alive than any other country. The effectiveness, availability and affordability of potent anti-retroviral therapy (ART) 
make it possible to contemplate ending the epidemic of HIV/AIDS. We consider what would have happened without ART, the 
impact of the current roll-out of ART, what might be possible if early treatment becomes available to all, and what could have 
happened if ART had been provided much earlier in the epidemic. 
 In 2013 the provision of  ART has reduced the prevalence of HIV from an estimated 15% to 9% among adults not on 
ART, the annual incidence from 2% to 0.9%, and the AIDS related deaths from 0.9% to 0.3% p.a. saving 1.5 million lives and 
US$727M. 
 Regular testing and universal access to ART could reduce the prevalence among adults not on ART in 2023 to 0.06%, 
annual incidence to 0.05%, and eliminate AIDS deaths. Cumulative costs between 2013 ands 2023 would increase by 
US$692M only 4% of the total cost of US$17Bn. 
 If a universal testing and early treatment had started in 1998 the prevalence of HIV among adults not on ART in 2013 
would have fallen to 0.03%, annual incidence to 0.03%, and saved 2.5 million lives. The cost up to 2013 would have increased 
by US$18Bn but this would have been cost effective at US$7,200 per life saved. 
 Future surveys of HIV among women attending ante-natal clinics should include testing women for the presence of 
anti-retroviral drugs, measuring their viral loads, and using appropriate assays for estimating HIV incidence. These data would 
make it possible to develop better and more reliable estimates of the current state of the epidemic, the success of the current 
ART programme, levels of viral load suppression for those on ART and the incidence of infection. 
 
Introduction 
The prevalence of HIV infection among women attending 
ante-natal clinics (ANC) in South Africa has increased 
logistically over time and in all provinces appears to have 
reached a steady state (Appendix 1). In the case of the Free 
State the prevalence of HIV infection has not changed for 
ten years. However, South Africa now has more people 
receiving anti-retroviral therapy than any other country in 
the world and this has undoubtedly had a significant 
impact on the epidemic. If the South African Government 
follows the current recommendations of the World Health 
Organization (WHO) and raises the CD4+ threshold for 
starting treatment from 350 to 500 cells/μL1 it will be 
important to estimate the further impact that this will have 
on the epidemic of HIV and how much it will cost. For 
completeness we also consider what would have happened 
if the South African government had implemented the 
treatment recommendations made by the International 
AIDS Society (IAS) in 19962,3 and the Department of 
Health and Human Services of the United States of 
America (DHHS) in 2000.3,4  
 In this paper we use trend data for the prevalence of 
HIV among women attending ante-natal clinics in South 
Africa and the reported coverage of anti-retroviral therapy. 
We fit these data to a dynamical model to estimate current, 
and to project future, trends in prevalence, incidence, 
treatment needs and deaths. We estimate the per capita 
cost of HIV/AIDS to the country including the cost of 
providing drugs and providing support to people on ART, 
and the cost of hospitalization and access to primary health 
care facilities. We do not include the social and economic 
costs incurred when people die of AIDS so that this 
calculation is conservative with regards to the overall cost 
to society. 
Data 
The model is fitted to data from the annual national 
surveys of HIV among women attending ante-natal clinics 
(ANCs).5-12 The prevalence of HIV is generally higher in 
pregnant women than in women in the general population 
and is higher in women than in men. The prevalence of 
infection among ANC women has therefore been scaled 
down to match the prevalence in all adults following 
UNAIDS.13 
Table 1. Cost of days in hospital, primary health care 
visits and counselling and testing from Granich et al.14 
Costs are for the year 2013. 
Item Cost ($ p.a.) 
Inpatient days  not on ART  568 
Inpatient days  on ART  138 
Primary health care visits not on ART   154 
Primary health care visits  on ART   269 
Counselling and testing per test  11 
Community support and care  150 
 
 Costs include hospitalization, primary health care and 
treatment.14 The costs are given in Table 1. We do not 
discount future costs because of the uncertainty in the 
economic future. However, the data presented here could 
be used to discount the costs and benefits at any desired 
rate.  
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Table 2. Annual drug costs for triple therapy in 
South Africa (US$). 
Year Cost (US$) 
1995  10,00015 
2003  1,70016 
2006    73017 
2009  18814 
2014  10018,19 
 
 The cost of combination ART has declined since it first 
became available as shown in Table 2. The cost data are 
fitted to a logistic curve in Figure 1. We assume that the 
cost of ART will converge to an asymptote of US$50 per 
year. Below that the drug costs are a small fraction of the 
total costs of care and support which we set to US$250 per 
year. 
 
 
 
 
 
 
 
Figure 1. Cost of ART in South Africa (blue 
dots) fitted to a logistic curve (red line). Data 
are in Table 1. 
Model 
The model is a standard dynamical model discussed in 
detail elsewhere.20,21 It includes uninfected people who are 
susceptible to infection while infected people go through 
four stages of infection to death to match the known 
Weibull survival for people infected with HIV but not 
ART.22 To account for heterogeneity in the risk of 
infection the transmission parameter declines 
exponentially with the prevalence of HIV.20,21 
Fitting the model 
We first fit the model to the prevalence data without 
including ART to get a null model against which to 
compare the impact of ART. We vary the prevalence of 
infection in 1980, which determines the timing of the 
epidemic, the rate of increase and the rate at which the risk 
of infection declines as the prevalence increases as this 
determines the peak value of the prevalence. The fitted 
values are in Table 3.  
 To model the current level of ART provision we 
assume that certain proportions of people in the third and 
fourth stages of HIV infection are started on ART. We 
assume that coverage increases logistically and we vary 
the rate and timing of the increase and the proportion of 
people starting treatment in each stage to match the 
reported coverage of ART.13 To explore the impact of 
active case finding we assume that coverage increases 
logistically at a realistic rate, timing and asymptotic 
coverage. We assume that all those that are found to be 
HIV-positive, in any stage of infection, are eligible for 
treatment. The parameter values are given in Table 4. 
Table 3. The birth, background mortality and transition 
rates are fixed;20 the other parameters are varied to 
optimize the fit to the trend in the prevalence of HIV 
shown in Figure 2 (below). 
Parameter Value 
Adult population in 2013 (M) 35.0 
Birth rate/yr 0.029 
Background mortality/yr 0.018 
Force of infection/yr 0.791 
Prevalence at which transmission is halved 0.052 
Transition rate/yr between HIV stages off ART 0.348 
Transition rate/yr between HIV stages on ART 0.087 
 
Table 4. Model parameters are for logistic functions. 
Coverage gives the asymptotic coverage; Rate the exponential 
rate of increase; Half-max the year when coverage reaches half 
the maximum value. OR is the odds-ratio for the number 
tested to the prevalence of HIV in that stage. 
 Parameter Value 
Coverage 0.75 
Rate per annum 0.60 
Half-max. (year) 2008.4 
 
Passive case 
finding: Stage 4 
 OR (testing) 1 
Coverage 0.35 
Rate per annum 0.81 
Half-max. (year) 2011.6 
Passive case 
Finding: Stage 3 
 
OR (testing) 2 
Coverage 0.90 
Rate per annum 2.00 
Half-max. (year) 2014.0 
Test interval (yrs) 1.00 
Active case finding: 
testing 
 
OR (testing) 10 
Coverage 0.90 
Rate per annum 2.00 Active case finding: take-up 
Half-max. (year) 2014.0 
  
 The model is set up so that a proportion of HIV-
positive people are tested a certain number of times each 
year and of those that test positive a proportion start ART. 
However, many people who are not infected will also be 
tested and in order to determine the cost of testing we need 
to know the case detection rate, that is the proportion of all 
those tested that are infected with HIV. Under passive 
case-finding people present to a health-service in stages 3 
or 4 of HIV infection. We assume that all those that 
present in stage 4 will be infected with HIV but that only 
50% of those that present in stage 3 will be infected with 
HIV. Under active case finding we assume that only 10% 
of those that are tested will be infected with HIV. Since we 
also have to avoid the mathematical possibility that we test 
more people than there are in the population we set the 
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odds ratio for the number tested to the number that are 
HIV-positive to 1 for stage 4, 2 for stage 3, and 10 for 
active case-finding; when the prevalence is low the 
number that are positive is 100%, 50% or 10%, 
respectively, of the number tested but when the prevalence 
is high the number tested in each test interval never 
exceeds the total population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Top row: baseline scenario without ART. Second row: current level of treatment. Third row: early treatment (see text for details). 
Bottom row: Early treatment starting in 1988 (see text for details).  Left: HIV prevalence. Blue: Data (with 95% confidence limits) and fitted 
line. Red: not on ART. Green: Data for those on ART and fitted line. Middle: HIV incidence. Red: Incidence of HIV. Green: incidence of 
treatment. Black: mortality not on ART. Grey: mortality on ART. Right: Cost. Green: ART. Red: Green plus hospitalization. Brown: Red 
plus cost of testing.  
Results 
The fitted data and implied trends are shown in Figure 2 
using the parameter values in Table 3 and Table 4. Figure 
2 gives, from left to right, the prevalence of infection, the 
incidence of infection and of treatment, and the costs. 
From top to bottom the graphs give the counterfactual that 
would have happened without ART, the impact of the 
current level of ART, the predicted impact of universal 
access to early treatment starting in 2014 and the impact of 
universal access to early treatment if it had started in 1998  
following the 1996 IAS2,3 and 2000 DHHS3,4 guidelines.  
Without ART 
Figure 2A gives the prevalence of HIV, Figure 2B the 
implied incidence (red line) and mortality (black line) and 
Figure 2C the implied costs of in-patient and out-patient 
care14 (red line). The prevalence rises rapidly to a steady 
state and remains fairly constant after 2005. The incidence 
peaks, declines as people start to die, and then levels off at 
about 1.4% per year.  The mortality rises about ten years 
Adult prevalence            Adult incidence (/year)                  Cost (US$/adult/year)
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after the incidence, reflecting the mean life-expectancy of 
people with HIV, and levels off at 1.2% per year. The 
annual cost to the health system would have increased 
steadily to US$50 per adult per year, or US$1.8Bn per 
year, in 2013 and then remained constant. 
Progress so far 
The provision of ART on a significant scale in the public 
sector in South Africa began in 2005 and expanded 
rapidly. Following the then recommendations of the World 
Health Organization (WHO)23 infected people only started 
ART when their CD4+ cell count fell to 200/μL or they 
were in clinical stages 3 or 4.24 In 2006 WHO increased 
the CD4+ cell count at which people could start ART to 
350/μL and the South African government followed suit. 
 Figure 2D gives the HIV prevalence of those not on 
ART (red line), the reported number of people on ART 
(green dots) the fitted number of people on ART (green 
line) and all infected people (blue line); Figure 2E gives 
the incidence of HIV (red line), the rate at which people 
start ART (green line), the mortality of those on ART 
(black line) and of those not on ART (grey line). Figure 2F 
gives the cost of ART (green line)14 and the cost of ART 
plus the cost of in-patient and out-patient care (red line). 
 Currently (2013), an estimated 14% of adults are 
infected with HIV (Figure 2D: blue line), the prevalence of 
HIV positive adults not on ART (Figure 2D: red line) has 
fallen to 8% and the prevalence on ART has increased to 
6%. If the current policy were to continue the prevalence 
of HIV positive adults not on ART would continue to fall 
to about 5%. 
 There has been a similarly large impact on incidence 
which has fallen from a peak of 2% per annum to 0.9% 
per annum in 2013 (Figure 2E: red line) with the rate at 
which people start ART peaking at 1.2% per annum in 
2010 (Figure 2E: green line) but falling rapidly after that. 
AIDS related deaths among adults peaked in 2006 at about 
0.9% per annum but by 2013 had fallen to 0.3% per 
annum (Figure 2E: black line). Without ART about 420 
thousand people would have died in 2013; the provision of 
ART has reduced this to 102 thousand saving more than 
318 thousand lives in 2013. People will continue to die on 
ART (Figure 2E: grey line) but mainly from natural causes 
other than HIV. 
 While the current ART provision has saved many lives 
and greatly reduced incidence, there has also been a 
substantial cost saving—the annual cost in 2013 has fallen 
from $50 per adult, what it would have been without ART, 
(Figure 2C: red line) to $41 per adult (Figure 2F: red line) 
for a net cost saving of about $315M in the year 2013 
alone. The total cost in 2013 is US$1.4Bn of which 44% is 
the cost of providing ART, including care and support, 
(Figure 2F: green line) and 56% is the cost of in-patient 
and out-patient care (Figure 2F: difference between red 
and green lines).  
Universal Access to Early Treatment 
The substantial impact of treatment on the incidence, 
prevalence and mortality due to AIDS and the savings that 
accrue, encourages one to consider the impact of making 
ART available to everyone, regardless of CD4+ cell 
counts. If the South African government chooses to adopt 
the 2013 guidelines of the World Health Organization25 
about 90% of all HIV-positive people will be eligible for 
treatment as soon as they are found to be HIV-positive. 
The current (2013) guidelines of the International AIDS 
Society26 and the Department of Health and Human 
Services (DHHS)27 both recommend treatment for those 
infected with HIV without regard to their CD4+ cell count 
on the grounds that this is in the best interests of the 
individuals concerned and has the added benefit of 
reducing the likelihood that they will infect their partners. 
We therefore consider what would happen under a policy 
of universal access in which 90% of all adults, not on 
ART, are tested each year and 90% of those that test 
positive are started on ART, with coverage and testing 
reaching half the target levels by the end of 2014 (Table 
4). 
 Universal access to early treatment should eliminate 
HIV transmission (Figure 2G and Figure 2H: red lines) 
and eliminate AIDS related deaths by 2018 (Figure 2H: 
black line) but there will still be a very large number of 
HIV positive people on ART (Figure 2G: green line) who 
will have to be maintained on treatment for the rest of their 
lives. The rate at which people need to be started on 
treatment will increase to about three times the present rate 
(Figure 2H: green line) in 2015 but after that will fall 
rapidly as transmission and the generation of new cases 
fell. The costs will begin to fall rapidly (Figure 2I: red and 
brown lines) as the prevalence of infection falls. There will 
be a small initial increase in costs as the backlog of 
untreated patients is taken up. The cumulative costs to 
2023 would increase by US$157M. South Africa currently 
spends about US$500 per capita on health so that a policy 
of early treatment will only increase overall costs by about 
0.8% of total spending on health up to 2023 but by then 
the annual cost will have fallen from $35 per adult, under 
the current policy to $31, per adult, under the policy of 
early treatment and after that there would be further cost 
savings.  
Starting treatment in 1998 
Finally, we make a comparison of what would have 
happened if a policy of early treatment had been started in 
1998 once triple combination therapy became available 
following the 1996 guidelines of the IAS and the 2000 
guidelines of the DHHS.3 The impact that this policy 
would have had is shown in the bottom row of Figure 2. 
By 2010 all HIV positive people would have been on ART 
(Figure 2J: red line) and incidence would have been 
eliminated (Figure 2K: red line). A massive campaign of 
testing and starting people on treatment would have been 
necessary (Figure 2K: green line) but by 2013 that would 
have been over. Costs would have been dominated by the 
high costs of treatment in 2000 (Figure 2L: green line) but 
by 2013 total costs would have fallen to US$29 per adult 
per year down from a total cost of US$1.4Bn per year to 
US$644M per year. 
Bringing it all together 
Figure 3 is a direct comparison of what would have 
happened without ART, what has happened as a result of 
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the roll-out of ART, what could happen under universal 
access and early treatment following the new WHO 
guidelines, and what could have happened if a policy of 
early treatment had been started in 1998 following the 
1996 recommendations of the IAS2 and the 2000 
recommendations of the DHHS.2,4 The current policy has 
saved, and will continue to save, both lives (Figure 3A and 
B) and money (Figure 3C and D). Universal access to 
early treatment will incur a small increase in costs as 
treatment is expanded (red and green lines (Figure 3C and 
D) but will save many more lives (Figure 3A and B) and, 
in the long run, save more money (Figure 3C and D), 
eliminate HIV and bring an end to AIDS related deaths 
(Figure 3A and B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. A: Annual mortality from AIDS; B: Cumulative mortality from AIDS; C: Annual cost of ART plus in-patient 
and out-patient care for AID related conditions; D: Cumulative costs of ART plus in-patient and out-patient care for AID 
related conditions. Blue line: counterfactual if ART had not been made available; Red line: continuation of current policy 
on ART provision; Green: provision of early treatment and universal access; Brown line: counterfactual if a policy of 
early treatment had been implemented in 1998.  
 
Discussion 
The government of South Africa has been successful in the 
extent to which it has made ART therapy available in the 
public sector and in negotiating drug prices. Currently, an 
estimated 2.1 million people are being kept alive on ART 
and the cost savings to the economy have been 
considerable. It is clear that expanding access will save 
more lives and, in the long run, will save money and 
eliminate HIV. 
 Universal access to early treatment is the only way to 
eliminate HIV in South Africa with currently available 
interventions.3 The two most critical issues are drug supply 
and compliance. A regular and reliable supply of drugs 
must be assured. Stock-outs will create anger and mistrust 
among infected people and poor compliance, for any 
reason, will lead to viral rebound, treatment failure, 
ongoing transmission and drug resistance. These two 
considerations must be at the forefront of plans to 
effectively control and eventually eliminate HIV. 
 Other methods of support and control can play an 
important role.3 To ensure high levels of compliance it will 
be necessary to deal with problems of stigma and 
discrimination and to ensure that there is strong 
community involvement and support for people living with 
HIV. Adult medical male circumcision will significantly 
reduce the prevalence of HIV among young men and have 
a secondary benefit for young women who are the group at 
greatest risk. Pre-exposure prophylaxis will provide 
additional protection for those that are unable to protect 
themselves as is often the case for women who believe that 
their partners may be infected but are unable to negotiate 
condom use. Condoms are highly effective if used 
properly and should be readily available to all that need 
them. Better control of other sexually transmitted 
infections is important in itself and will contribute further 
to the control of HIV. And while these interventions can 
make an important contribution to stopping the epidemic 
of HIV, universal access to early treatment provides an 
ideal entry point for each of them. Finally, by developing 
programmes that are firmly based in local communities it 
will be possible to provide training and education while 
employing community outreach workers thereby creating 
jobs and stimulating local economies. 
 It remains important to ensure the validity or otherwise 
of these results and to improve the model predictions. Here 
we have used the reported coverage of ART but this has 
never been directly measured. To do so all women who 
A  B 
 
 
 
 
 
 
 
 
 
 
C  D 
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test positive for HIV in the annual ante-natal clinic surveys 
should be tested for the presence of anti-retroviral drugs, 
their viral loads should be measured and an incidence 
assay should be used to estimate incidence. We have also 
assumed a cost of US$250 per year for care and support of 
those infected with HIV. The results are sensitive to this 
assumption but this level of cost could be achieved if there 
is effective community support and mobilization. If this 
money were used to train and employ community health 
workers it would create jobs and provide an important 
stimulus to local economies in the poorest communities. 
 What will be needed is a big push as and when the 
Department of Health adopts the new WHO guidelines. 
Since an estimated 90% of all HIV positive people will 
then be eligible for immediate treatment it would be 
advisable to abandon the use of CD4+ cell counts but to 
make viral load testing more widely available as a way of 
assessing the impact of the programme and of monitoring 
compliance. This analysis suggests that the rate at which 
people are currently being started on ART will have to be 
increased by about four times, but only for about two 
years. While this will require considerable organization it 
will only incur a marginal increase in costs for about five 
years and within a few years the savings in lives and 
money will be substantial. 
 What is needed now is informed leadership, a 
programme of universal testing and immediate access to 
treatment, combined with good operational research, while 
monitoring the impact and implementation of the new 
programme. The sooner that this is undertaken the more 
lives and money that will be saved. South Africa has the 
wherewithal to stop the epidemic; all that is needed is the 
commitment and determination to achieve an AIDS Free 
Generation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Prevalence of infection in women attending ante-natal clinics in South Africa. When fitting the data the points 
marked orange appear to be outlier and have not been included. EC: Eastern Cape; FS; Free State; GT: Gauteng; KZ: 
KwaZulu-Natal; MP: Mpumalanga; NC: Northern Cape; LP: Limpopo; NW: North West; WC: Western Cape. 
 
Appendix 1 
The annual ante-natal clinic surveys in South Africa, started 
by Horst Küstner,5-12 provide the best data on trends in the 
prevalence of HIV anywhere in the world. In all nine 
provinces in South Africa the prevalence of HIV has 
levelled off and is not declining with the possible exception 
of Gauteng (Figure 4). However, the timing and the extent 
of the epidemics varies among provinces. The epidemic in 
KwaZulu-Natal stabilized at 39% and reached half this 
value in March 1996. The epidemic in the Western Cape 
stabilized at 18% and only reached half this value in 
December 2000, almost four years later than in KwaZulu-
Natal. The prevalence of HIV among women attending 
ante-natal clinics now appears to be stable in all provinces 
and, in the case of the Free State, has been stable for ten 
years. 
 The most plausible explanation for this is that the 
epidemic was introduced into in South Africa via trucking 
routes from Lusaka in Zambia to Durban in KwaZulu-
Natal. In 1987 the prevalence of HIV among gold miners 
from Malawi was 4% but in men from all other countries, 
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including South Africa, was less than 0.1%.28 When this 
became known the mines stopped recruiting men from 
Malawi.29 This could explain the observation that the 
epidemic started in the Free State and parts of Gauteng 
bordering on the Free State after KwaZulu-Natal but before 
the other provinces. 
Table 5. Parameters for the fits to the provinces given in Figure 4. 
EC: Eastern Cape; FS: Free State; GT: Gauteng; KN: KwaZulu-
Natal; LM: Limpopo; MP: Mpumalanga; NC: Northern Cape; 
NW: North West; WC: Western Cape 
 
Rate of 
increase/yr 
Doubling 
time (yr) Asymptote 
Time to half-
maximum (yr)
EC 0.547 1.27 0.286 1998.34 
FS 0.606 1.14 0.312 1996.54 
GT 0.632 1.10 0.303 1996.68 
KN 0.544 1.27 0.388 1996.22 
LM 0.513 1.35 0.213 1999.73 
MP 0.660 1.05 0.343 1996.65 
NC 0.593 1.17 0.168 1997.90 
NW 0.572 1.21 0.298 1997.26 
WC 0.481 1.44 0.176 2000.97 
 
 It is probable that the main reason why the countries of 
southern Africa have the highest rates of HIV in the world 
is because of the system of oscillating migrant labour30 
which also provided the economic basis for Apartheid. Men 
are recruited from rural areas all over southern Africa and 
may spend much of their adult lives living without their 
wives or families. The rural areas experienced poverty and 
social disruption because of the lack of adult men and the 
men often had little to occupy them and to provide intimacy 
and social support apart from alcohol and sex.31 This is 
supported by data for the Western Cape in 2001. Of the 
women attending public ante-natal clinics 62% were 
coloured and 37% were black. The overall prevalence of 
HIV was 8.8% but the prevalence of HIV among coloured 
women was 1.2% (0.7%−2.0%) and among black women 
was 21.6% (18.4%−25.3%). While conditions in the black 
townships may be worse than in the coloured townships the 
main difference is that the coloured townships are well 
established and have relatively stable populations while in 
the black townships there is a considerable and ongoing in 
and out migration from the Eastern Cape to the Western 
Cape. 
Appendix 2 
The World Health Organization guidelines25 of 2013 advise 
HIV-positive people to start ART if their CD4+ cell count 
is less than 500/μL, if they have TB or Hepatitis B, if they 
are pregnant, under the age of five years, or in a sero-
discordant relationship. Data on the distribution of CD4+ 
cell counts in HIV-negative people32 suggest that about 
80% of all those currently infected with HIV in South 
Africa and not on ART will have a CD4+ cell count below 
500/μL. If we include the other groups of people that 
should start treatment irrespective of their CD4+ cell count, 
then about 90% of all HIV positive people are currently 
eligible for ART. 
 If there is a need to triage people in order to treat those 
at greatest risk first, the sensible way to do this would be on 
the basis of each person’s viral load. Individual CD4+ cell 
counts can vary by an order of magnitude within 
populations,32 the mean CD4+ cell count can vary by a 
factor of two between populations,32 and survival is 
independent of the initial CD4+ cell count.32,33 CD4+ cell 
counts therefore have very little prognostic value except in 
that unfortunate circumstance when the count is very low 
by which time an infected person is likely to be in WHO 
clinical stages III or IV and in need of immediate treatment 
anyway. Considerable savings in time, human resources 
and money could be had by abandoning the use of CD4+ 
cell counts for deciding on when to start ART. People with 
a high viral load, on the other hand, have a reduced life 
expectancy34 and are more infectious than those with a low 
viral load.35 It would therefore have the greatest benefit for 
individual patients and have the greatest impact on 
transmission if preference was given to people with high 
viral loads if the availability of anti-retroviral drugs is 
limited.36 
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